IN2015DN00962A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00962A
IN2015DN00962A IN962DEN2015A IN2015DN00962A IN 2015DN00962 A IN2015DN00962 A IN 2015DN00962A IN 962DEN2015 A IN962DEN2015 A IN 962DEN2015A IN 2015DN00962 A IN2015DN00962 A IN 2015DN00962A
Authority
IN
India
Prior art keywords
compound
formula
medicament
description
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Lilli Anselm
David Banner
Wolfgang Haap
Bernd Kuhn
Thomas Luebbers
Jens Uwe Peters
Beat Spinnler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2015DN00962A publication Critical patent/IN2015DN00962A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
IN962DEN2015 2012-08-21 2013-08-19 IN2015DN00962A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21
PCT/EP2013/067218 WO2014029722A1 (en) 2012-08-21 2013-08-19 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
IN2015DN00962A true IN2015DN00962A (zh) 2015-06-12

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN962DEN2015 IN2015DN00962A (zh) 2012-08-21 2013-08-19

Country Status (24)

Country Link
US (1) US9409882B2 (zh)
EP (1) EP2888244A1 (zh)
JP (1) JP2015530997A (zh)
KR (1) KR20150044947A (zh)
CN (1) CN104583198A (zh)
AR (1) AR092172A1 (zh)
AU (1) AU2013305102A1 (zh)
BR (1) BR112015003217A2 (zh)
CA (1) CA2879796A1 (zh)
CL (1) CL2015000354A1 (zh)
CO (1) CO7200259A2 (zh)
CR (1) CR20150073A (zh)
EA (1) EA025166B1 (zh)
HK (1) HK1206716A1 (zh)
IL (1) IL237128A0 (zh)
IN (1) IN2015DN00962A (zh)
MA (1) MA37893A1 (zh)
MX (1) MX2015002026A (zh)
PE (1) PE20150995A1 (zh)
PH (1) PH12015500262A1 (zh)
SG (1) SG11201500900YA (zh)
TW (1) TW201412728A (zh)
WO (1) WO2014029722A1 (zh)
ZA (1) ZA201500625B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047842T2 (hu) * 2016-02-26 2020-05-28 Hoffmann La Roche Új pirrolidin származékok
PT3575284T (pt) 2017-01-24 2021-10-01 Astellas Pharma Inc Composto de prolinamida substituído por fenildifluorometilo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
JP2008526840A (ja) 2005-01-06 2008-07-24 アストラゼネカ アクチボラグ 新規化合物
WO2007086001A2 (en) 2006-01-24 2007-08-02 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
WO2008141119A2 (en) * 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
CA2706576A1 (en) 2007-11-30 2009-06-04 F. Hoffmann-La Roche Ag Pyridine compounds
US20110028448A1 (en) 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
PE20120911A1 (es) * 2009-04-20 2012-08-06 Hoffmann La Roche Derivados de prolina como inhibidores de catepsina
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
EP2760833A1 (en) 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives

Also Published As

Publication number Publication date
IL237128A0 (en) 2015-03-31
PH12015500262A1 (en) 2015-03-30
WO2014029722A1 (en) 2014-02-27
ZA201500625B (en) 2016-08-31
EA201590363A1 (ru) 2015-06-30
CR20150073A (es) 2015-03-13
TW201412728A (zh) 2014-04-01
EP2888244A1 (en) 2015-07-01
MA37893A1 (fr) 2017-08-31
KR20150044947A (ko) 2015-04-27
CO7200259A2 (es) 2015-02-27
BR112015003217A2 (pt) 2017-07-04
SG11201500900YA (en) 2015-03-30
CA2879796A1 (en) 2014-02-27
CN104583198A (zh) 2015-04-29
CL2015000354A1 (es) 2015-10-23
US20150307472A1 (en) 2015-10-29
AR092172A1 (es) 2015-03-25
JP2015530997A (ja) 2015-10-29
EA025166B1 (ru) 2016-11-30
AU2013305102A1 (en) 2015-02-12
US9409882B2 (en) 2016-08-09
HK1206716A1 (zh) 2016-01-15
MX2015002026A (es) 2015-06-05
PE20150995A1 (es) 2015-06-29

Similar Documents

Publication Publication Date Title
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
PH12015501083B1 (en) Novel pyridine derivatives
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
PH12015501843A1 (en) Novel pyrazol derivatives
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
PH12015501933A1 (en) Novel pyridine derivatives
MX2014004920A (es) Nuevos derivados de pirazina.
IN2015DN01061A (zh)
IN2014DN06104A (zh)
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
MX2014008141A (es) Amidas macrociclicas como inhibidores de proteasas.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
IN2014DN10669A (zh)
MX363458B (es) Nuevos derivados de tetrazolona.
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
MX2014008918A (es) Nuevos derivados de pirrolidina.
MY175703A (en) Tablets with improved acceptance and good storage stability
IN2015DN00962A (zh)
MX351093B (es) Nuevos derivados de azetidina.
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA79010U (ru) Применение n -стеароилэтаноламина в качестве вещества с активным антигриппозным действием